Amyris sees promising results for intranasal RNA/NLC vaccine

August 22, 2021 |

In California, Amyris, Inc. achieved promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI), which means an effective Covid-19 nose spray vaccine could become reality.

In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI RNA vaccine generates antibodies and provides upper respiratory protection for SARS-CoV-2 (COVID-19), which Amyris believes has the potential to provide fuller protection against current variants of SARS-CoV-2. The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu.

If approved and commercialized, the Amyris/IDRI RNA vaccine is targeted to be more accessible to people in underserved countries. In addition, the intranasal vaccine may offer improved upper respiratory protection beyond currently approved vaccines.

Print Friendly, PDF & Email

Tags: , , ,

Category: Fuels

Thank you for visting the Digest.